Popular Trials
Behavioural Intervention
Xenon Inhalation Therapy for Depression
This trial is testing whether inhaling xenon gas can help people with treatment-resistant depression. The study is comparing the effects of adding xenon to treatment as usual to adding nitrogen to treatment as usual.
Behavioural Intervention
Healthy Lifestyles for Bipolar Disorder
This trial aims to compare the effects of two different healthy lifestyles on people with bipolar disorder. The trial will investigate the acceptability of time-restricted eating and the Mediterranean diet for those who are already taking
Ketamine for Bipolar Disorder
This trial will study the effects of four doses of ketamine on people with treatment-resistant bipolar disorder, to see if it is an effective, safe and tolerable treatment. The primary outcome will be change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores from baseline to day 14.
NMDA receptor antagonist
IM Ketamine vs Midazolam for Suicidal Thoughts
This trial tests whether a shot of ketamine can quickly reduce suicidal thoughts in depressed adults who visit the emergency room. These patients are at high risk of suicide and need fast-acting treatment. Ketamine works by quickly changing brain chemicals to improve mood and reduce suicidal thoughts. It has been found to rapidly reduce depressive symptoms and suicidal thoughts, making it a potential fast-acting treatment for suicidality.
Popular Filters
Trials for BD Patients
Positive Airway Pressure Device
APAP for Obstructive Sleep Apnea in Mental Illness
This trial is testing a treatment called Positive Airway Pressure (PAP) for adults with serious mental illnesses like schizophrenia and bipolar disorder who also have sleep apnea. PAP treatment uses a machine to help keep the airways open during sleep by providing a steady stream of air through a mask. The study aims to see if this treatment can improve cognitive function and overall health in these patients over several months. Positive Airway Pressure (PAP) is the standard and most effective treatment for obstructive sleep apnea (OSA).
Cannabinoid
Medical Cannabis for Chronic Pain
This trial will investigate if medical cannabis can effectively reduce pain and improve quality of life for patients with chronic conditions. The study will gather data through an online questionnaire about patients' use of cannabis and its effects. Medical cannabis interacts with the body's natural system to help manage pain and other symptoms. Medical cannabis has been increasingly studied and used as an alternative treatment for managing chronic pain, with numerous studies supporting its potential benefits.
Lurasidone for Cognitive Improvement in Bipolar Disorder
This trial is testing whether lurasidone can help improve thinking and memory in people with bipolar disorder who are currently stable but have cognitive problems. The medication works by balancing brain chemicals. Lurasidone has shown potential in improving thinking and memory in both schizophrenia and bipolar disorder.
Trials for Schizoaffective Disorder Patients
Positive Airway Pressure Device
APAP for Obstructive Sleep Apnea in Mental Illness
This trial is testing a treatment called Positive Airway Pressure (PAP) for adults with serious mental illnesses like schizophrenia and bipolar disorder who also have sleep apnea. PAP treatment uses a machine to help keep the airways open during sleep by providing a steady stream of air through a mask. The study aims to see if this treatment can improve cognitive function and overall health in these patients over several months. Positive Airway Pressure (PAP) is the standard and most effective treatment for obstructive sleep apnea (OSA).
Behavioural Intervention
Smoking Cessation App for Mental Health Disorders
This trial will test a new smartphone app called Quit on the Go, designed to help people with serious mental illness quit smoking. The study will compare this app to traditional methods, with both groups also using nicotine patches and gum. The goal is to see if the app helps more people quit smoking and if it is cost-effective.
Behavioural Intervention
Dexmedetomidine vs Lorazepam for Agitation in Schizophrenia or Bipolar Disorder
This trial compares the effects of a drug (dexmedetomidine) to a known drug (lorazepam) in treating agitation in people with schizophrenia or bipolar disorder.
Phase 3 Trials
NMDA Antagonist
Ketamine for Bipolar Depression and Suicidal Thoughts
This trial tests a treatment that starts with a ketamine injection to quickly reduce severe depression and suicidal thoughts, followed by maintenance pills. It targets patients with severe bipolar depression who need rapid symptom relief. Ketamine rapidly alters brain activity, and the pills help maintain these positive changes. Ketamine has shown effectiveness as a rapid-acting antidepressant with antisuicidal effects, but evidence for long-term maintenance therapy is limited.
NMDA Antagonist
NRX-101 for Bipolar Depression
This trial tests a two-step treatment for adults with severe bipolar depression and suicidal thoughts. It starts with a quick-acting ketamine dose followed by an oral medication to maintain improvement. The goal is to see if this approach is better than using lurasidone alone. Ketamine has been shown to rapidly reduce depressive and suicidal symptoms in both unipolar and bipolar depression.
Lurasidone for Cognitive Improvement in Bipolar Disorder
This trial is testing whether lurasidone can help improve thinking and memory in people with bipolar disorder who are currently stable but have cognitive problems. The medication works by balancing brain chemicals. Lurasidone has shown potential in improving thinking and memory in both schizophrenia and bipolar disorder.
Alpha-2 Adrenergic Receptor Agonist
Dexmedetomidine for Agitation in Schizophrenia and Bipolar Disorder
This trial tests an investigational medication for treating episodes of agitation in bipolar I/II, schizophrenia, schizoaffective and schizophreniform disorder. It compares the drug to a placebo.
Atypical Antipsychotic
Lumateperone for Schizophrenia and Bipolar Disorder
This trial is being conducted at multiple locations worldwide and will last for 26 weeks. It aims to evaluate the safety and tolerability of lumateperone in children with schizophrenia or bipolar disorder.
Trials With No Placebo
Positive Airway Pressure Device
APAP for Obstructive Sleep Apnea in Mental Illness
This trial is testing a treatment called Positive Airway Pressure (PAP) for adults with serious mental illnesses like schizophrenia and bipolar disorder who also have sleep apnea. PAP treatment uses a machine to help keep the airways open during sleep by providing a steady stream of air through a mask. The study aims to see if this treatment can improve cognitive function and overall health in these patients over several months. Positive Airway Pressure (PAP) is the standard and most effective treatment for obstructive sleep apnea (OSA).
Cannabinoid
Medical Cannabis for Chronic Pain
This trial will investigate if medical cannabis can effectively reduce pain and improve quality of life for patients with chronic conditions. The study will gather data through an online questionnaire about patients' use of cannabis and its effects. Medical cannabis interacts with the body's natural system to help manage pain and other symptoms. Medical cannabis has been increasingly studied and used as an alternative treatment for managing chronic pain, with numerous studies supporting its potential benefits.
NMDA Antagonist
NRX-101 for Bipolar Depression
This trial tests a two-step treatment for adults with severe bipolar depression and suicidal thoughts. It starts with a quick-acting ketamine dose followed by an oral medication to maintain improvement. The goal is to see if this approach is better than using lurasidone alone. Ketamine has been shown to rapidly reduce depressive and suicidal symptoms in both unipolar and bipolar depression.
View More Related Trials
Frequently Asked Questions
Introduction to bipolar disorder
What are the top hospitals conducting bipolar disorder research?
Bipolar disorder, a complex mental health condition characterized by alternating periods of extreme highs and lows, is the focus of groundbreaking clinical trials conducted by top hospitals around the world. In Toronto, the Centre for Addiction and Mental Health leads the way with five active bipolar disorder trials and an impressive track record of eight completed studies since their first recorded trial in 2002. Meanwhile, in Houston, Texas, The University of Texas Health Science Center takes on this challenging condition with four ongoing trials and has made significant progress since embarking on research in 2015. Not far behind is the University of Texas at Austin, also contributing to our understanding of bipolar disorder through their current four clinical trials while pioneering investigations into this illness only began recently in 2019.
Moving across states to Ann Arbor, Michigan, researchers at the esteemed University of Michigan are actively engaged in three bipolar disorder trials as they build upon fifteen previous studies that have shaped our knowledge since initiating their first investigation back in 2009. Finally yet importantly,Toronto Western Hospital joins forces with its counterparts at home boasting three active clinical trials dedicated to better understanding bipolar disorder; these efforts started alongside those initiated by CAMH all those years ago back in2002.
These leading institutions exemplify a commitment to advancing our comprehension and treatment options for individuals living with bipolar disorder - helping countless patients find stability and improve their quality of life. By conducting cutting-edge research and collaborating across borders, these hospitals provide hope not just for those directly affected by this condition but also for future generations seeking effective interventions.
Which are the best cities for bipolar disorder clinical trials?
Toronto, Ontario, Austin (Texas), and Houston (Texas) emerge as the top cities for bipolar disorder clinical trials. Toronto leads with 13 ongoing studies focusing on treatments like Cannabidiol, Ketamine Hydrochloride, and other therapeutic approaches. Following closely behind are Austin and Houston with 10 and 8 active trials respectively investigating interventions such as NRX-101, Alcohol treatment options, and more. These cities offer individuals dealing with bipolar disorder access to cutting-edge research opportunities that may contribute to improved management of this condition.
Which are the top treatments for bipolar disorder being explored in clinical trials?
Promising breakthroughs in bipolar disorder treatment are emerging from ongoing clinical trials. Ketamine, a powerful drug initially listed in 2013, is currently being explored in three active trials for bipolar disorder. With its potential to alleviate symptoms and enhance mood stability, ketamine holds great promise as a novel therapeutic approach. Another exciting avenue of research is continuous Theta Burst Stimulation (cTBS), which made its first appearance on the scene in 2021. Already involved in two active trials focusing on bipolar disorder, cTBS shows potential as a non-invasive treatment option that could revolutionize how we manage this complex condition. As these studies progress, we move closer to finding more effective treatments for individuals living with bipolar disorder.
What are the most recent clinical trials for bipolar disorder?
Exciting strides are being made in the field of bipolar disorder research, with recent clinical trials offering new possibilities for treatment. One promising trial involves a combination of ketamine and perampanel, demonstrating potential benefits for individuals with bipolar disorder. Another study explores the effectiveness of inositol as a therapeutic option across different phases of the disorder. Additionally, ketamine is being evaluated in a Phase 3 trial to further understand its impact on bipolar disorder symptoms. Furthermore, an active treatment involving dexmedetomidine shows promise as it progresses through Phase 4 testing. Lastly, cariprazine holds potential as an intervention for individuals with bipolar disorder based on positive results observed during Phase 4 studies. These advancements offer hope and may pave the way towards improved management and quality of life for those living with this condition.
What bipolar disorder clinical trials were recently completed?
Recent clinical trials focusing on bipolar disorder have yielded significant findings, paving the way for improved treatments. In May 2022, the Medical University of South carolina successfully completed a trial investigating the potential benefits of N-Acetyl cysteine. Additionally, in August 2019, the University of California, San Diego concluded a trial examining Varenicline's efficacy in managing bipolar disorder symptoms. Furthermore, Yale University wrapped up their Ketamine study in November 2018. These pioneering studies underline ongoing efforts to enhance our understanding and treatment options for individuals with bipolar disorder.